Molecular Profiling of Bladder Tumors Based on the Detection of FGFR3 and TP53 Mutations

Journal of Urology

Volumn 176, Issue 6, 2006, Pages 2686-2689

  Lamy, A ^a   Gobet, F ^a   Laurent, M ^a   Blanchard, F ^a   Varin, C ^a   Moulin, C ^a   Andreou, A ^a   Frebourg, T ^b   Pfister, C ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

biological; bladder; bladder neoplasms; mutation; tumor markers

Indexed keywords

FIBROBLAST GROWTH FACTOR 3; PROTEIN P53;

ARTICLE; BLADDER TUMOR; CANCER GRADING; CONTROLLED STUDY; EXON; FIBROBLAST GROWTH FACTOR RECEPTOR 3 GENE; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; TP53 GENE; TUMOR RECURRENCE; YEAST;

AGED; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENES, P53; GENOTYPE; HUMANS; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SEQUENCE ANALYSIS, DNA; URINARY BLADDER NEOPLASMS;

EID: 33751024894     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.07.132     Document Type: Article

References (20)

1. Spruck C.H., Ohneseit P.F., Gonzales-Zuleta M., Esrig D., Miyao N., Tsai Y.C., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54 (1994) 784
2. Braithwaite A.W., Royds J.A., and Jackson P. The p53 story: layers of complexity. Carcinogenesis 26 (2005) 1161
3. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23 (1999) 18
4. Naski M.C., Wang Q., Xu J., and Ornitz D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 13 (1996) 233
5. Bakkar A.A., Wallerand H., Radvanyi F., Lahaye J.B., Pissard S., Lecerf L., et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63 (2003) 8108
6. Van Rhijn B.W., Van der Kwast T.H., Vis A.N., Kirkels W.J., Boeve E.R., and Zwarthoff E.C. FGFR3 and TP53 characterize alternative genetic pathways in pathogenesis of urothelial cell carcinoma. Cancer Res 64 (2004) 1911
7. Kurth K.H., Denis L., Bouffioux C., Sylvester R., Debruyne F.M.J., Pavone-Macaluso M., et al. Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 31 (1985) 1840
8. Cote R.J., and Chatterjee S.J. Molecular determinants of outcome in bladder cancer. Cancer J 5 (1999) 4
9. Pfister C., Moore L., Allard P., Larue H., Lacombe L., Têtu B., et al. Predictive value of cell cycle markers p53, MDM2, p21 and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 5 (1999) 4079
10. Van Rhijn B.W., Vis A.N., Van der Kwast T.H., Kirkels W.J., Radvanyi F., Ooms E.C., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21 (2003) 1912
11. Flaman J.M., Frebourg T., Moreau V., Charbonnier F., Martin C., Chappuis P., et al. A simple p53 functional assay for screening cell lines, blood and tumors. Proc Natl Acad Sci 92 (1995) 3963
12. Parmar M.K.B., Freedman L.S., Hargreave T.B., and Tolley D.A. Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 142 (1989) 284
13. Allard P., Bernard P., Fradet Y., and Têtu B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 81 (1998) 692
14. Olumi A.F. A critical analysis of the use of p53 as a marker for management of bladder cancer. Urol Clin North Am 27 (2000) 75
15. Pfister C., Flaman J.M., Martin C., Grise P., and Frebourg T. Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors. J Urol 161 (1999) 1973
16. Dekairelle A.F., Tombal B., Cosyns J.P., and Gala J.L. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder. Clin Cancer Res 11 (2005) 4724
17. Billerey C., Chopin D., Aubriot-Lorton M.H., Ricol D., Gil Diez de Medina S., Van Rhijn B., et al. Frequent FGFR3 mutations in papillary non invasive bladder (pTa) tumors. Am J Pathol 158 (2001) 1995
18. Hernandez S., Lopez-Knowles E., Lloreta J., Kogevinas M., Jaramillo R., Amoros A., et al. Real FX, FGFR3 and TP53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 11 (2005) 5444
19. Brake M., Loertzer H., Horsch R., and Keller H. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 163 (2000) 1697
20. Soloway M.S., Sofer M., and Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167 (2002) 1573